Published in J Clin Invest on June 07, 2010
Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther (2014) 1.77
Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Mol Psychiatry (2016) 1.38
Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. J Neurosci (2011) 0.99
Distinct activation properties of the nuclear factor of activated T-cells (NFAT) isoforms NFATc3 and NFATc4 in neurons. J Biol Chem (2012) 0.91
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88
Nerve growth factor (NGF) regulates activity of nuclear factor of activated T-cells (NFAT) in neurons via the phosphatidylinositol 3-kinase (PI3K)-Akt-glycogen synthase kinase 3β (GSK3β) pathway. J Biol Chem (2014) 0.83
Lithium chloride promotes host resistance against Pseudomonas aeruginosa keratitis. Mol Vis (2013) 0.81
Inhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells. J Biol Chem (2014) 0.80
Up-regulation of NFATc4 involves in neuronal apoptosis following intracerebral hemorrhage. Cell Mol Neurobiol (2013) 0.80
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. CNS Spectr (2013) 0.79
Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. PLoS One (2013) 0.79
Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases. Schizophr Bull (2016) 0.79
The Emerging Roles of the Calcineurin-Nuclear Factor of Activated T-Lymphocytes Pathway in Nervous System Functions and Diseases. J Aging Res (2016) 0.78
Control of neuronal apoptosis by reciprocal regulation of NFATc3 and Trim17. Cell Death Differ (2014) 0.78
Investigating interventions in Alzheimer's disease with computer simulation models. PLoS One (2013) 0.77
Involvement of 'stress-response' kinase pathways in Alzheimer's disease progression. Curr Opin Neurobiol (2014) 0.76
Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J Clin Invest (2016) 0.76
Inhibition of glycogen synthase kinase-3β prevents sympathetic hyperinnervation in infarcted rats. Exp Biol Med (Maywood) (2015) 0.75
Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling. Br J Cancer (2017) 0.75
Death receptors: signaling and modulation. Science (1998) 16.95
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 8.37
The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci (2004) 7.92
Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol (1991) 6.89
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J (1990) 6.23
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (2001) 6.12
Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2008) 5.37
Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science (1997) 4.99
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet (2001) 3.84
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol (2009) 3.33
Nuclear localization of NF-ATc by a calcineurin-dependent, cyclosporin-sensitive intramolecular interaction. Genes Dev (1997) 3.29
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature (1999) 3.21
The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol (2006) 3.17
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci (2004) 3.12
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. Proc Natl Acad Sci U S A (2003) 2.82
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
Dynamic markers of altered gait rhythm in amyotrophic lateral sclerosis. J Appl Physiol (1985) (2000) 2.76
Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology (2002) 2.64
Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci (2009) 2.60
Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci (2003) 2.54
Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell (2003) 2.54
Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A (1999) 2.41
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol Cell Biol (2002) 2.30
Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J Exp Med (1992) 2.27
The transcription factor NFAT4 is involved in the generation and survival of T cells. Immunity (1998) 2.13
GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci (2009) 2.11
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun (2001) 2.08
Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods (1997) 2.04
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 1.92
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92
Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med (2002) 1.85
A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord (2009) 1.83
Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 1.80
Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity (2000) 1.79
Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity (2000) 1.74
Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J Immunol (1999) 1.65
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A (2005) 1.64
GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis (2006) 1.62
Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci U S A (2005) 1.59
Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroeng Rehabil (2005) 1.49
Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ (2008) 1.46
Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry (1999) 1.46
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett (1997) 1.44
Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord (2002) 1.41
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry (2004) 1.39
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest (2009) 1.32
Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J Biol Chem (1999) 1.28
Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther (2003) 1.26
Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol Behav (2004) 1.24
No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS. PLoS One (2009) 1.23
Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem (2008) 1.18
Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci (2005) 1.18
Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci (2002) 1.15
Signaling by death receptors in the nervous system. Curr Opin Neurobiol (2008) 1.13
Alternative splicing and expression of human and mouse NFAT genes. Genomics (2008) 1.12
Lithium's effect in forced-swim test is blood level dependent but not dependent on weight loss. Behav Pharmacol (2007) 1.09
Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc Natl Acad Sci U S A (1989) 1.08
Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. J Neurosci (2008) 1.08
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008) 1.04
A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J Biol Chem (2005) 1.03
Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci (2004) 1.02
Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod (2004) 1.02
Lithium's antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol (2009) 0.94
NF-ATc2 induces apoptosis in Burkitt's lymphoma cells through signaling via the B cell antigen receptor. Eur J Immunol (2003) 0.92
Is lithium still worth using? An update of selected recent research. Harv Rev Psychiatry (2002) 0.89
Regulation of the stability and transcriptional activity of NFATc4 by ubiquitination. FEBS Lett (2008) 0.85
Functional effects of myoblast implantation into histoincompatible mice with or without immunosuppression. J Physiol (1995) 0.83
Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis (2008) 0.83
Lithium in ALS: from the bench to the bedside. Amyotroph Lateral Scler (2008) 0.82
Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia. Biol Psychiatry (1984) 0.80
Lithium treatment in Alzheimer's disease does not promote cognitive enhancement, but may exert long-term neuroprotective effects. Psychopharmacology (Berl) (2009) 0.78
Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci (2003) 1.83
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain (2010) 1.77
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration. FASEB J (2009) 1.33
GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol (2009) 1.32
Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci (2006) 1.21
Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer's disease. J Biol Chem (2003) 1.19
Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease. J Neurosci (2005) 1.18
N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem (2007) 1.15
Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. J Neurosci (2010) 1.10
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging (2005) 1.05
Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci (2004) 1.04
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J (2007) 1.04
Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol (2004) 1.03
The role of GSK3 in Alzheimer disease. Brain Res Bull (2009) 1.00
GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus (2010) 0.99
Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain. J Neurochem (2006) 0.98
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. J Neurosci (2011) 0.98
Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic Biol Med (2010) 0.94
GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging (2003) 0.91
Increased neurotransmitter release at the neuromuscular junction in a mouse model of polyglutamine disease. J Neurosci (2011) 0.91
Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox Res (2004) 0.88
GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88
Age-dependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels. Exp Neurol (2012) 0.87
Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur J Neurosci (2002) 0.86
Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus. Brain (2013) 0.84
In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning. EMBO J (2014) 0.82
Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. Hum Mol Genet (2013) 0.81
BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. J Neurosci Res (2007) 0.81
α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. Hum Mol Genet (2011) 0.81
Presynaptic dysfunction in Huntington's disease. Biochem Soc Trans (2010) 0.81
Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent. PLoS One (2013) 0.79
Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. Brain Res (2009) 0.79
Assembly in vitro of tau protein and its implications in Alzheimer's disease. Curr Alzheimer Res (2004) 0.78
Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. Neurobiol Dis (2009) 0.78
Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo. Trends Neurosci (2004) 0.78
Mutant huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes. Exp Neurol (2012) 0.77
Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. Mol Neurobiol (2014) 0.76
Tau kinase I overexpression induces dentate gyrus degeneration. Neurodegener Dis (2010) 0.76
Testing the possible inhibition of proteasome by direct interaction with ubiquitylated and aggregated huntingtin. Brain Res Bull (2006) 0.75
A mouse model to study tau pathology related with tau phosphorylation and assembly. J Neurol Sci (2007) 0.75
Sulfo-glycosaminoglycan content affects PHF-tau solubility and allows the identification of different types of PHFs. Brain Res (2002) 0.75
Transgenic mouse models with tau pathology to test therapeutic agents for Alzheimer's disease. Mini Rev Med Chem (2002) 0.75